Future studies should evaluate the long-term effects of MAPT-ASO treatment on neuronal connectivity and synaptic function, as well as its efficacy in in vivo models of Alzheimer’s disease. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.